NCT07161843尚未招募2 期
Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure
Ebima Clifford Okundaye1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2026年6月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Rate of change in creatinine glomerular filtration rate
研究概览
简要总结
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 10 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized patients
- •presence of Acute renal failure
- •Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of >2%
- •willingness to participate
排除标准
- •High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status
研究组 & 干预措施
Use of QRX-3 in addition to standard therapy
Experimental
QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days
干预措施: QRX-3 (Drug)
control group
Placebo Comparator
placebo twice daily will be given to this group in addition to standard therapy
干预措施: QRX-3 (Drug)
结局指标
主要结局
Rate of change in creatinine glomerular filtration rate
时间窗: 28 days
compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients
次要结局
- daily change in glomerular filtration rate in ml/min(7 days)
- daily change in cystatin C level in mg/dl(7 days)
研究者
Ebima Clifford Okundaye
President
Neukidney Inc.
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseAlzheimer's DiseaseNCT07011745Bristol-Myers Squibb426
招募中
3 期
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Alzheimer DiseaseNCT06585787Karuna Therapeutics, Inc., a Bristol Myers Squibb company406
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineManiaBipolar DisorderNCT07140913Bristol-Myers Squibb424
已完成
3 期
ong-term safety and efficacy of TK-023 in Patients with Severe Dementia of the Alzheimer's TypeDementia of the Alzheimer's typeJPRN-jRCT2080224612TEIKOKU SEIYAKU Co., LTD.70
已完成
3 期
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or ScalpActinic KeratosesNCT03285477Almirall, S.A.351